Quaternary nanoparticles enable sustained release of bortezomib for hepatocellular carcinoma.

Ling LiYicheng ZhangYang ZhouHaijie HuYizong HuChristos GeorgiadesHai-Quan Mao Florin M Selaru

Published in: Hepatology (Baltimore, Md.) (2022)

The BTZ-NP formulation provides a potent and safe treatment of HCC via a localized delivery approach. These results warrant additional preclinical studies to advance this technology to human clinical trials.

Keyphrases

clinical trial
endothelial cells
multiple myeloma
induced pluripotent stem cells
randomized controlled trial
newly diagnosed
combination therapy
phase ii
anti inflammatory
double blind